argenx Liabilities 2024

argenx Aktienanalyse

What does argenx do?

Argenx SE is a biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of serious diseases. The company was founded in 2008 and is headquartered in Gent, Belgium. Argenx utilizes an innovative technology platform, the Simple Antibody platform, to develop customized antibodies with high efficacy. Argenx operates in two main business areas: clinical development and licensing. The company aims to produce outstanding therapeutic agents from each of its platform technologies and drug candidates, which can be used as antibody therapies against serious autoimmune diseases or cancer. Argenx's main product is the drug Efgartigimod, a monoclonal antibody developed for the treatment of multiple autoimmune diseases, particularly generalized Myasthenia Gravis (GMG). The drug is currently in clinical development. In recent years, Argenx has made significant progress in the development of new drugs. For example, the company has announced the discovery of new antibodies for the treatment of Myasthenia Gravis, rheumatoid arthritis, and various types of cancer. Licensing these development pipelines opens up new opportunities for Argenx to create additional therapy options for patients with serious illnesses. Argenx has also established partnerships with leading pharmaceutical companies such as Shire and AbbVie to expand its technology platform and drug candidates into new areas of application. The company is currently working on the development of therapies for rare and serious diseases that have no satisfactory treatment options. With the advancement of its innovative technology platform and the expansion of its portfolio of drug candidates, Argenx is on a promising path to play a leading role in the industry. The company is building an extensive network of partnerships and collaborations to accelerate the further development of its technology platform and products, and to achieve further success in the search for new therapeutic applications and areas of application. Looking ahead, Argenx is poised to play a significant role in the biopharmaceutical industry, particularly in the development of personalized therapy options for the treatment of serious diseases where no satisfactory treatment options currently exist. Argenx is proud of its dedicated team of employees who strive every day to realize the company's vision - to help patients cope with serious illnesses through new and innovative therapies. Output: Argenx SE is a biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of serious diseases. argenx ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing argenx's Liabilities

argenx's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating argenx's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing argenx's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

argenx's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in argenx’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about argenx stock

What is the level of liabilities of argenx this year?

argenx has a debt balance of 444.95 M USD this year.

What were the liabilities of argenx compared to the previous year?

The liabilities of argenx have increased by 38.8% increased compared to the previous year.

What are the consequences of high debt for investors of argenx?

High liabilities can pose a risk for investors of argenx, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in argenx?

Low liabilities mean that argenx has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of argenx affect the company?

An increase in liabilities of argenx can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of argenx affect the company?

A decrease in the liabilities of argenx can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of argenx?

Some factors that can influence the liabilities of argenx include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of argenx so important for investors?

The liabilities of argenx are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can argenx take to modify the liabilities?

To change its liabilities, argenx can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does argenx pay?

Over the past 12 months, argenx paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, argenx is expected to pay a dividend of 0 USD.

What is the dividend yield of argenx?

The current dividend yield of argenx is .

When does argenx pay dividends?

argenx pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of argenx?

argenx paid dividends every year for the past 0 years.

What is the dividend of argenx?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is argenx located?

argenx is assigned to the 'Health' sector.

Wann musste ich die Aktien von argenx kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of argenx from 10/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/6/2024.

When did argenx pay the last dividend?

The last dividend was paid out on 10/6/2024.

What was the dividend of argenx in the year 2023?

In the year 2023, argenx distributed 0 USD as dividends.

In which currency does argenx pay out the dividend?

The dividends of argenx are distributed in USD.